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Abstract
Exome and genome sequencing were used to identify the genetic etiology of a severe
neurodevelopmental disorder in two unrelated Ashkenazi Jewish families with three
affected individuals. The clinical findings included a prenatal presentation of micro-
cephaly, polyhydramnios and clenched hands while postnatal findings included micro-
cephaly, severe developmental delay, dysmorphism, neurologic deficits, and death in
infancy. A shared rare homozygous, missense variant (c.274A > G; p.Ser92Gly,
NM_024516.4) was identified in PAGR1, a gene currently not associated with a Men-
delian disease. PAGR1 encodes a component of the histone methyltransferase MLL2/
MLL3 complex and may function in the DNA damage response pathway. Complete
knockout of the murine Pagr1a is embryonic-lethal. Given the available evidence,
PAGR1 is a strong candidate gene for a novel autosomal recessive severe syndromic
neurodevelopmental disorder.
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1 | INTRODUCTION
PAGR1 encodes for PAXIP1-associated glutamate-rich protein 1, which
is a component of a Set1-like multiprotein histone methyltransferase
complex (Kumar et al., 2014). Its roles remain elusive with diverse
proposed biological mechanisms of action. It was first identified in a
complex with PAX-Interacting Protein 1 (PAXIP1; also known as PTIP)
by co-immunoprecipitation and mass spectrometry (Cho et al., 2007).
Both proteins were found to be associated with MLL3/MLL4-containing
histone H3K4 methyltransferase complexes, suggesting a role in epige-
netic gene regulation. In addition, PAGR1 and PAXIP1 form a separate
complex that plays a role in DNA repair (Gong et al., 2009). PAGR1 also
acts as a transcriptional co-regulator of the estrogen and glucocorticoid
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receptors (Liang et al., 2009; Zhang et al., 2013), a function thought to
be independent of its association with PAXIP1 or MLL3/MLL4.
While the biological functions of this protein are obscure, studies in
animal models suggest this gene plays a key role in early development.
In zebrafish, loss of function of this gene is associated with reduced
brain ventricle size, and less distinctly defined midbrain-hindbrain
boundary (Blaker-Lee et al., 2012). Null mice do not survive beyond
early stages of embryogenesis (four to five somite). They have abnormal
development of extra-embryonic tissues including the amnion, chorion
and visceral yolk sac. At the molecular level, Pagr1a null embryos have
reduced expression of Bmp2, a known regulator of extraembryonic
development, and reduced expression of the forebrain marker Otx2 and
Six3 during neural development (Kumar and others 2014). In addition, a
recent study demonstrated that deletion of Pagr1 in pre-adipocytes pre-
vents the induction of C/EBPβand C/EBPδ and disrupts adipogenesis
and muscle development (Lee et al., 2020).
To date, PAGR1 has not been associated with any Mendelian dis-
order. Here we present details of three individuals from two unrelated
families of Ashkenazi Jewish (AJ) ancestry, harboring the same homo-
zygous missense variant in the PAGR1 gene, who demonstrated a clin-
ically similar neurodevelopmental phenotype.
2 | METHODS
2.1 | Exome sequencing
Family A: Following written informed consent and IRB approval, exome
analysis was performed on DNA extracted from amniocentesis of the
proband (female fetus) and parents in family A (trio exome). Exonic
sequences from genomic DNA were enriched with the SureSelect
Human All Exon 50 Mb V5 Kit (Agilent Technologies, Santa Clara, Cali-
fornia, USA). Sequences were generated on a HiSeq2500 sequencing
system (Illumina, San Diego, California, USA) with 125 bp paired-end
runs. Read alignment and variant calling were performed with
DNAnexus (Palo Alto, California, USA) using default parameters with
the human genome assembly hg19 (GRCh37) as reference. Filtering
was performed as described elsewhere (Abu-Libdeh et al., 2021).
Exome analysis of the proband yielded 53 million reads, with a mean
coverage of 78X, and 94% over 20X.
Family B: Clinical exome sequence analysis of the two affected
siblings (males) and their parents (quad exome) done in 2014 was
non-diagnostic. The details of the methodologies were previously
described (Retterer et al., 2016).
2.2 | Whole Genome sequencing
For family A, next generation sequencing (NGS) libraries were pre-
pared with an Illumina PCR-free TruSeq DNA Library Prep Kit, from
the proband's genomic DNA. Sequences were generated on an
Illumina NovaSeq 6000 sequencing platform as 150 bp paired-end
reads, to a final depth of 30X coverage. The FASTQs were uploaded
into the Geneyx (previously TGex) Analysis platform (Dahary et al.,
2019). Alignment and variant calling of single nucleotide variants
(SNVs), copy number variants (CNVs) and structural variants (SVs),
and repeats were called using Illumina DRAGEN Bio-IT. The resulting
VCF file were comprehensively annotated on the Geneyx Analysis
annotation engine, and presented for analysis, filtering and interpreta-
tion. Variant prioritization was performed using VarElect (Stelzer
et al., 2016).
Written informed consents were obtained for family B and
research whole genome sequencing was performed on the peripheral
blood DNA samples from the two affected siblings and the unaffected
parents. Sequencing methods and variant filtering criteria were previ-
ously described (Okur et al., 2019). The candidate variants and their
familial segregation with the clinical phenotype were confirmed by
Sanger sequencing.
2.3 | Segregation analysis
The region containing the PAGR1 variant was amplified by PCR using
the genomic DNA from the members of the two families and analyzed
by Sanger dideoxy nucleotide sequencing.
2.4 | Haplotype analysis
Using family B's genome sequencing data, a 3 Mb region
(Chr16:27816799–31,816,799, hg38) centered on the PAGR1 vari-
ant was queried for variants (GQ >30, variant allele fraction >0.2).
Almost all the variants in this region were homozygous in
both affected individuals in family B indicating a stretch of
homozygosity, and the parents were heterozygous at these posi-
tions (Supplemental Table 2). The results were compared with the
variants in the proband from family A and homozygous stretches
common to the affected individuals of the two families were
identified.
2.5 | Carrier frequency analysis
31,513 anonymous blood samples were obtained from the Dor
Yeshorim screening program, from around the world (including the
United States of America [New York, New Jersey, Maryland, Califor-
nia, Illinois, Florida, Ohio, and Michigan], Canada, Mexico, Argentina,
Brazil, UK, Belgium, France, Switzerland, Austria, Australia,
South Africa, and Israel) (Ekstein and Katzenstein 2001). All partici-
pants provided written consent for research. The consent included
that the participant samples would be used for clinical testing and
residual material would be de-identified to use for research purposes
to characterize single gene disorders in the Ashkenazi Jewish
population.
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3 | RESULTS
3.1 | Clinical Reports
The clinical features seen in the three affected individuals from the
two families are listed in Table 1.
Family A. A healthy non consanguineous couple of Ashkenazi
Jewish (AJ) descent, with one healthy child, was referred for genetic
counseling during their second pregnancy because of sonographic
findings in the third trimester including moderate polyhydramnios,
clenched hands, and microcephaly (head circumference 0.6th centile,
cerebellum 2-3rd centile) (Figure 1A, individual II-2). The pregnancy
was relatively normal initially with nuchal translucency of 1.1 mm and
a low integrated risk for trisomy 21 (1:20,000) followed by a normal
second trimester anatomy scan. However, at the 24th week there was
a small head (head circumference 1st centile) with presumed normal
corpus callosum, vermis and cerebellum.
The pregnancy was terminated at week 32. Post-mortem exami-
nation showed a sloping forehead, micrognathia and clenched hands
(Figure 1B, panel 1).
Family B. The two affected individuals were brothers, sons of a
consanguineous healthy Ashkenazi Jewish couple. The proband
(Figure 1A, II-2) presented at birth with multiple congenital anomalies
including hydrocephalus, low-lying conus medullaris, coarctation of
the aorta, and flexion contractures (Figure 1B, panel 2). The preg-
nancy, including anatomy scan, was reportedly normal. The baby was
delivered at 40 weeks and 2 days of gestation with Apgar scores of
9 and 9 at 1 and 5 minutes. His birth weight was 2055 grams (<5th
centile), length was 46.5 cm (~5th centile), and head circumference
was 26.5 cm (<<5th centile). He was noted at birth to have normal
tone but a weak suck. Dysmorphic features were noted, including
microcephaly with a sloping forehead and overriding sutures,
hypotelorism, large, low-set ears posteriorly rotated, bulbous nose
with broad nasal bridge, high arched palate, short neck with excess
skin folds, wide spaced nipples, bilateral simian crease, overlapping
fingers with hypoplastic nails, a sacral dimple, cryptorchidism, inverted
and medially rotated feet, and overlapping of toes.
He was admitted to the neonatal intensive care unit for medical
management and was found to be hypertonic. Spinal ultrasound dem-
onstrated a low-lying conus medullaris. Chest x-ray demonstrated
TABLE 1 Clinical features of the three affected individuals harboring homozygous variant in PAGR1
Individual 1 (Family A) Individual 2 (Family B) Individual 3 (Family B)
Parental ancestry Ashkenazi Jewish
Consanguinity No Yes
Family history None None Affected brother
Gravida, Parity G2P1 G2P1 G3P2




1.1 mm NA Thick
Integrated test 1:20,000 NA NA
Second trimester:





Second anomaly scan Normal CC and vermis.
Cerebellum 8%
Reported normal Small for gestational age
24th week HC 1%, normal CC, vermis &
cerebellum 8%
Intrauterine growth restriction
Pregnancy outcome Termination of pregnancy A delivery of a baby boy at 40 + 2 weeks A delivery of a baby boy at 39 + 2 weeks
Birth weight NA 2055 gr (<5%ile) 2450 gr (3-5%ile)
Apgar score NA 9/9 8/9
Birth HC (%) NA 26.5 cm (<<5%ile) 31 cm (<5%ile)
Clinical description Dysmorphic features as detailed in text
Additional findings NA Aortic coarctation with PDA
Outcome NA Died at 10 months of age due to cardiac
arrest following a surgery
Died at 3 months of age of cardiac arrest
m/p d/t to aspiration
Development NA No milestones





NM_024516.4: c.[274A > G];[274A > G]
NP_078792.1: p.[(Ser92Gly)];[(Ser92Gly)]
Abbreviations: CC – corpus callosum, CMA – chromosomal microarray analysis, d/t – due to, HC – head circumference, HMZ – homozygous, m/p – most probably,
NA – not available, ROH-region of homozygosity.
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thin, gracile ribs. Echocardiogram at two days of age demonstrated
aortic coarctation, a large patent ductus arteriosus (PDA), and a patent
foramen ovale with bidirectional flow; follow-up echocardiogram four
days later demonstrated that both the coarctation and PDA had
resolved. Renal ultrasound was normal. Head ultrasound on the sec-
ond day of life was normal. Brain MRI on day of life six was normal.
Electroencephalogram (EEG) on day 22nd of life demonstrated sub-
clinical seizures, and he was started on phenobarbital. Repeat EEG
two days later was negative for seizure activity. He was noted to have
aphonia on his sixth day of life. Laryngoscopy was inconclusive. He
had a G-tube placed at one month of age as he tolerated minimal oral
intake. His course was complicated by multiple episodes of central
apnea and chronic respiratory failure for which a tracheotomy tube
was placed at two months of age. He was transferred to a rehabilita-
tion facility and was not found to meet any developmental milestones.
At 10 months of age, he was taken to surgery due to an infection at
the gastrostomy-tube site. He had a cardiac arrest following surgery
and died. Genetic evaluation included a fluorescent in-situ
hibridization analysis for chromosomes 13, 18, 21 X, and Y, which was
normal, and a chromosome microarray analysis which showed long
regions of homozygosity consistent with the parental consanguinity.
The brother of the proband presented prenatally with similar features
(Figure 1A, B, II-3). An increased nuchal fold was noted on a 15-week ultra-
sound. He was reported at 20 weeks gestation to be small for gestational
age and at 24 weeks of gestation was found to have intrauterine growth
restriction. At 30 weeks of gestation, he was found to have microcephaly,
low set ears, echogenic bowel, possible anal atresia, clenched hands, and
sluggish fetal movement. He was delivered at 39 weeks 2 days gestation
with Apgar scores of 8 and 9 at 1 and 5 minutes, respectively. His birth
weight was 2450 grams (3–5th centile), length 45.5 cm (3–5th centile), and
head circumference of 31 cm (<<5th centile). At birth, he was noted to
have normal tone but a weak suck. He had dysmorphic features including
microcephaly with sloping forehead, small palpebral fissures, large, low-set
ears with over-folded prominent lobes, bulbous nose, high arched palate,
retrognathia, short neck, wide spaced nipples, bilateral undescended testi-
cles, and positional bilateral talipes equinovarus.
He was admitted to the neonatal intensive care unit for medical
management. He was found to have hypertonia and a failed his hearing
screen. Head ultrasound on his first day of life demonstrated decreased
sulcal patterning suggestive of prematurity, though he was full term.
Brain MRI on his fifth day of life demonstrated a punctate focus of
restricted diffusion in the brain parenchyma suggestive of a small acute
infarction; there were no gross structural abnormalities. EEG was nega-
tive for seizure activity. Echocardiogram showed a small atrial septal
defect versus patent foramen ovale. Renal ultrasound was normal. Spi-
nal ultrasound was normal and did not demonstrate evidence of a teth-
ered cord. He was discharged to rehabilitation on nasogastric tube
feeding. He was reported not to achieve any developmental milestones.
He died at 3 months of age of cardiac arrest presumed to be secondary
to aspirations. Clinical quad exome sequencing (both affected siblings
and the parents) originally reported in June 2014 was non-diagnostic.
3.2 | Identification of a homozygous variant in
PAGR1
For family A, amniocentesis was performed at the 28th week, prior to ter-
mination. Chromosomal microarray analysis showed normal female
F IGURE 1 Molecular genetics and pictures of the affected individuals. 1a. Pedigrees of both Ashkenazi Jewish families. 1b. Pictures of the
three affected individuals; the terminated fetus of family A and two affected males of family B. Notice the resemblance of the clenched hands,
small chin and sloping forehead related to microcephaly. 1c. Sanger sequencing results for the PAGR1 variant in the members of family B
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karyotype and trio-exome sequencing analysis revealed a single homozy-
gous missense variant, in PAGR1 (chr16:29828120-A-G, hg19,
NM_024516:c.274A>G, p.Ser92Gly, rs375215655). Sanger sequencing
(Figure 1C) revealed both parents and the healthy sibling to be heterozy-
gous carriers. This variant was present within a relatively small region of
homozygosity on chromosome 16 (Chr16:29–31.4 Mb, hg19). In order to
comprehensively assess all the possible genetic etiologies, whole genome
sequencing of the proband from family A (Figure 1A, II-2) was performed.
The analysis, which included SNVs, CNVs and SVs did not reveal any
other candidates apart from the homozygous PAGR1 variant. A focused
analysis of the homozygous block encompassing the PAGR1 variant
(chr16:29,725,143-31,470,540, hg 19) did not reveal any other rare vari-
ants in the coding region, nor any suspected copy/structural variants.
For family B, whole genome sequencing analysis of the affected
sibs identified candidate rare variants including homozygous missense
changes in PAGR1, KDM8, and SLC12A3 and a hemizygous variant in
PRPS2 (Supplemental Table 1). The SLC12A3 variant was deprioritized
based on the phenotypic differences when compared to the clinical
features associated with this gene (Gitelman syndrome [MIM
263800]). We initially focused on PRPS2 and PAGR1. The PRPS2 vari-
ant was present in the unaffected brother (data not shown) which
resulted in eliminating this candidate. Segregation of the PAGR1 vari-
ant in the unaffected sibling (II-1; Figure 1C) and phenotype compari-
sons resulting from Genematcher matches (Sobreira et al., 2015), led
to the prioritization of the PAGR1 homozygous missense variant
(chr16:29828120-A-G, hg19, NM_024516.4:c.274A > G, p.Ser92Gly)
as the strongest candidate for the phenotype in the affected siblings.
Notably, this variant was present within a region of homozygosity on
chromosome 16 (Chr16:19.29–85.94 Mb, hg19) as seen in the chro-
mosomal microarray results for the individual II-2.
The PAGR1 c.274A > G; p.Ser92Gly variant is present at a very low
allele frequency in GnomAD v2 (allele frequency 0.00008307, 17/204636
heterozygotes) and v3 (allele frequency 0.00008544, 13/152158 hetero-
zygotes) databaseswith no homozygous individuals Upon clinical presenta-
tion it was deposited in the ClinVar database as a likely pathogenic variant
(accession number SCV001733594.1). This variant is in the conserved
PAXIP1_C domain of the protein and has the following in silico prediction
scores Provean 3.48 (damaging), SIFT 0 (damaging), REVEL 0.2119
(benign), MetaSVM 0.5887 (tolerated), CADD (GRCh38-v1.6) 24.8 and
GERP 5.34. The Serine 92 amino acid residue is conserved in organisms
includingXenopus, zebrafish, mouse, dog and elephant.
Analysis of SNP genotypes in a 3 Mb region flanking the PAGR1 vari-
ant showed shared homozygous variants in a sub-region (chr16:2978
6327–30,169,169 [hg38], ~382Kb), in the three affected individuals from
the two families (family A II-2, family B II-2, II-3) indicating a shared contigu-
ous stretch of homozygosity (Supplemental Tables 2 and 3).
3.3 | Carrier frequency of the PAGR1 variant in
Ashkenazi Jews
To determine the carrier frequency of the PAGR1 variant in the Jewish
population, 31,513 individuals were screened (22,909 fully Ashkenazi
Jewish, 4813 Sephardi Jewish, and 3791 mixed Ashkenazi Jewish/
Sephardi Jewish). Out of the 22,909 fully Ashkenazi samples, fifty-
eight were heterozygous, with a carrier frequency of 1/394 (an allele
frequency of 0.0012). Out of the 3791 Ashkenazi/Sephardi individ-
uals, one sample was heterozygous. There were no carriers within the
4813 individuals of Sephardi Jewish descent. Homozygous individuals
for the PAGR1 variant were not detected in any of the cohorts.
4 | DISCUSSION
We describe three affected individuals from two unrelated Ashkenazi
Jewish families with a homozygous missense variant in PAGR1
(c.274A>G; p.Ser92Gly; rs375215655). The phenotypes of the
affected individuals from both families are similar and include micro-
cephaly, distal arthrogryposis with clenched hands, and micrognathia.
PAGR1 maps to the 16p11.2 recurrent region (BP4-BP5) wherein
microdeletions and microduplications are associated with a broad
range of neurodevelopmental impairments, including autism, intellec-
tual disability, language disorders, and sensory symptoms (Al-Jawahiri
et al., 2019; Jenkins et al., 2016; Kim et al., 2020; Niarchou et al.,
2019; Shinawi et al., 2010; Steinman et al., 2016) (MIM 611913,
614,671). Several studies have examined the role of PAGR1 in the
neurocognitive phenotype of 16p11.2 copy number variants, includ-
ing a recent one on fetal cortical neurogenesis (Morson et al., 2021).
Review of the microarray-based “BrainCloud” dorsolateral prefrontal
cortex transcriptome found PAGR1 to be ubiquitously expressed with
predominant expression in the cerebellum, and its expression is signif-
icantly enriched in the fetal period as compared to the postnatal
period (Birnbaum et al., 2014).
While not much is known about PAGR1 and its function in
humans, several studies in model organisms suggest its clinical impor-
tance. In zebrafish, reduced expression of PAGR1 (referred as
c16orf53) was associated with reduced brain ventricle size, in addition
to less sharply defined midbrain-hindbrain boundaries (Blaker-Lee
et al., 2012). A recent study in mice revealed that expression of the
cognate mouse gene Pagr1a is found predominantly in the extraem-
bryonic and chorionic ectoderm from pre-gastrulation stages and
shows high expression within the embryo. In addition, homozygous
knock out mice are non-viable and do not develop beyond the four-
to five-somite stage (Lee et al., 2020).
However, so far, there are no human Mendelian phenotypes
associated with the bi-allelic disruption of PAGR1. Assessing the prob-
ability of PAGR1 causing an autosomal dominant disease using the
DOMINO software (Quinodoz et al., 2017) deems the gene to be
‘very likely recessive’. This is despite the relatively high pLI of the
gene (0.74) and low (0.11) observed/expected ratio in gnomADv2.1.1
(https://doi.org/10.1038/s41586-020-2308-7e). Additionally, homo-
zygous loss of function variants were not seen for PAGR1 gene in
gnomADv2.1.1, gnomADv3.1.1, TOPMed and GME variome (Scott
et al., 2016) population databases.
The PAGR1 missense variant (c.274A > G; p.Ser92Gly) is localized
to a highly conserved region in a Glu-rich domain of unknown
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function. Although the variant is very rare in the general population, it
is more common in the Ashkenazi Jewish population, with an allele
frequency of 0.00173 (https://doi.org/10.1038/s41586-020-2308-7),
and no reported homozygous individuals. This variant was part of a
region of homozygosity in the three affected individuals from the two
unrelated families (family A – II-2, family B – II-2, II-3), indicating a
shared ancestral chromosome with the variant.
Considering all the above, we suggest c.274A > G in PAGR1 is a
new candidate Ashkenazi Jewish founder variant for a severe reces-
sive disorder manifested by microcephaly, distal arthrogryposis and
developmental delay. We hypothesize that this missense variant might
retain some residual function (representing a hypomorphic allele),
enabling viability to term. Further functional studies are needed in
order elucidate the role of PAGR1 in human diseases.
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